Author:
Chan AdenKa-Yin,Zhang RikiRui-Qi,Aibaidula Abudumijiti,Shi ZhiFeng,Chen Hong,Mao Ying,Ng HoKeung
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial;eClinicalMedicine;2024-03
2. Astrocytoma (CNS WHO grade 4), IDH‐mutant with co‐occurrence of BRAF p.V600E mutation, and homozygous loss of CDKN2A;Neuropathology;2023-02-08
3. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial;The Lancet Oncology;2022-01
4. Diagnostic, Prognostic and Predictive Biomarkers in Gliomas;Principles of Neuro-Oncology;2020-12-24
5. Additional genetic alterations in BRAF-mutant gliomas correlate with histologic diagnoses;Journal of Neuro-Oncology;2020-09